



Biotech and Life Sciences Update in Maryland

Kelly Schulz
CEO, Maryland Tech Council



Maryland is Historically a Life Sciences Leader

- Maryland is a Top 3 Biopharma Region in the US¹
 - 52,000 life sciences workers
 - 3,300 companies
 - Federal assets: NIH and FDA
- Average wage is \$142,243 – 94% higher than the state's private sector average.
- Historically, a top destination for life sciences R&D.

GEN Genetic Engineering & Biotechnology News

3. BioHealth Capital Region (Maryland, Virginia, and Washington, D.C.)

The BioHealth Capital Region has generated enough positive news to retain the number-three ranking it **earned** and **celebrated** last year.

QIAGEN and Frederick County, MD, officials on July 12 announced completion of a 40,000-square-foot expansion of the company's Frederick, MD, facility, creating a 75,000-square-foot site focused on

next-generation sequencing, genomics, clinical healthcare, and forensics.

AstraZeneca is investing \$300 million in a new manufacturing facility in Rockville, MD, with plans to create 150 new jobs when the site opens in 2026.



Bristol Myers Squibb shuttered its Cancer Immunology and Cell Therapy Thematic Research Center within Woodside Technology Park in Redwood City, CA, in April. [BioMed Realty]

1. Genetic Engineering & Biotechnology News, July 24, 2024



Industry Investments in Maryland



Opened a \$300 million cell therapy manufacturing center in Gaithersburg



Opened a \$286 million biosafety testing facility in Rockville



UM BioPark opened 4MLK, a 250,000 sq. ft. life sciences hub in Baltimore



Expanded 18,000 sq. ft. endotoxin assay production facility in Walkersville



Expanded to 17,000 sq. ft. biodefense production facility in Frederick



Three Challenges



Lack of Growth



**Global
Competition**



**Policy
Challenges**



Challenge: We lag in the nation in growth

Across industry subsectors, Maryland business formation has not kept pace with the national average since 2019.

Sector	Maryland Growth	National Average
Bioscience Distribution	16.8%	35.0%
Medical Devices	17.9%	32.1%
Pharmaceuticals	39.5%	52.7%
Research & Testing Labs	33.2%	61.4%


Source: TECONOMY/BIO 2024 Maryland State Report



Challenge: We lag competing states in growth

Since 2019, Maryland's total bioscience industry business formation growth has failed to keep pace with competing states.

Source: TECONOMY/BIO 2024 State Reports






Challenge: Investments moving to competing states

- Industry has announced **\$158 billion** in new US manufacturing investments this year. **Maryland has received \$0.**
- 8 of the 11 states with PDABs have received \$0.

Where Pharma is Spending US Manufacturing Dollars

As pharmas announce billions in investment to boost U.S. manufacturing, the money is being split among a handful of states.



Source: Company reports • Chart by Annalee Armstrong

This chart is being updated as more companies make manufacturing announcements. Latest update: May 8, 2025.





Challenge: Federal Policies Slowing Innovation

NIH Budget Cuts

- NIH indirect cost grants were cut from up to 80% to just 15%
- Significant impact on MD research institutes
- Est. \$712 million funding loss and 3,076 job losses in MD¹

FDA Layoffs

- 3,500 employees cut
- Industry reports:
 - Lab inspections delays
 - Delayed approval of clinical trial amendments
 - Reduced communication from FDA to industry

Most Favored Nation

Status

- U.S. must pay same rate as countries with similar size and wealth.
- Canada uses MFN and has access to only about 11% of new cancer drugs, while the U.S. is closer to 90%.²

1. The Science & Community Impacts Mapping Project

2. Canada Health Policy Institute, "New Cancer Drugs in Canada 2012-2021," April 2023



Challenge: Losing Ground to China

- For the first time ever, China has surpassed the U.S. in clinical drug trials.
- Seven out of 10 clinical trials in China are sponsored by a Chinese biotech company.¹
- This year, 37% of molecules licensed by major pharmaceutical companies are projected to originate from China.²

“China is quickly ascending to biotechnology dominance. To remain competitive, the U.S. must take swift action in the next three years. Otherwise we risk falling behind, a setback from which we may never recover.”

National Security Commission on Emerging Biotechnology,
“Charting the Future of Biotechnology,” April 2025

1. GlobalData, Large pharma drug licensing from China reaches record high, April 2025

2. Stifel, Biopharma Market Update, March 31, 2025



Challenge: PDAB Process and Transparency

- Drugs were selected in private and based on data not made available to the public
- No data made available about Maryland patients who use the selected drugs
- Insufficient opportunity for engagement
 - Patients and stakeholders sought opportunity to speak for more than 90 seconds.
- Manufacturers were not given enough information about drug selection to correct any inaccuracies.



Opportunities

INVEST IN TALENT

Industry has sought talent solutions for years.

BioHub Maryland fills biopharma manufacturing workforce gap.

GOOD POLICY

Avoid price controls, punitive taxes, and anti-innovation policies that discourage industry investment in Maryland.

WIN ON COST

Maryland is less expensive than the Top 2 biopharma markets – Boston and San Francisco.

Fast-growing markets still need to build out costly infrastructure.

RETAIN > ATTRACT

Competing states are aggressively recruiting MD companies due to Tech Tax and other factors.

MD must actively work to retain existing life sciences employers.

Thank You



**MARYLAND
TECH COUNCIL**

ADVANCING LIFE SCIENCES AND TECHNOLOGY

**Learn More At
www.mdtechcouncil.com**